{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:51:34Z","timestamp":1786981894116,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11523-025-01129-5","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T23:28:05Z","timestamp":1742513285000},"page":"371-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CIBMTR Registry Data on Inotuzumab Ozogamicin Treatment in Patients with ALL Who Proceeded to Hematopoietic Stem Cell Transplant\u2014A Podcast"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-4522","authenticated-orcid":false,"given":"Marcos","family":"de Lima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"1129_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwillger","year":"2017","unstructured":"Terwillger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7: e577.","journal-title":"Blood Cancer J"},{"key":"1129_CR2","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","volume":"106","author":"JM Rowe","year":"2005","unstructured":"Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood. 2005;106:3760\u20137.","journal-title":"Blood"},{"key":"1129_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","volume":"157","author":"JI Sive","year":"2012","unstructured":"Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial. Br J Haematol. 2012;157:463\u201371.","journal-title":"Br J Haematol"},{"key":"1129_CR4","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/CM9.0000000000001898","volume":"135","author":"W Sun","year":"2022","unstructured":"Sun W, Huang X. Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy. Chin Med J. 2022;135:890\u2013900.","journal-title":"Chin Med J"},{"key":"1129_CR5","first-page":"3599","volume":"92","author":"E Carreras","year":"1998","unstructured":"Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 1998;92:3599\u2013604.","journal-title":"Blood"},{"key":"1129_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fimmu.2020.00489","volume":"11","author":"F Bonifazi","year":"2020","unstructured":"Bonifazi F, Barbato F, Ravaioli F, et al. Diagnosis and treatment of VOD\/SOS after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:489.","journal-title":"Front Immunol"},{"key":"1129_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.596134","volume":"10","author":"AI Antar","year":"2020","unstructured":"Antar AI, Otrock ZK, Dalle IA, et al. Pharmacologic therapies to prevent relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Front Oncol. 2020;10: 596134.","journal-title":"Front Oncol"},{"key":"1129_CR8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"J-H Dalle","year":"2016","unstructured":"Dalle J-H, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22:400\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1129_CR9","unstructured":"FDA Besponsa prescribing information."},{"key":"1129_CR10","unstructured":"EMA Besponsa summary of product characteristics."},{"key":"1129_CR11","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"H Kantarijian","year":"2019","unstructured":"Kantarijian H, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474\u201387.","journal-title":"Cancer"},{"key":"1129_CR12","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","volume":"4","author":"HM Kantarjian","year":"2017","unstructured":"Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4:e387\u201398.","journal-title":"Lancet Haematol"},{"key":"1129_CR13","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1111\/bjh.17029","volume":"191","author":"RD Cassaday","year":"2020","unstructured":"Cassaday RD, Marks DI, DeAngelo DJ, et al. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020;191:e77\u201381.","journal-title":"Br J Haematol"},{"key":"1129_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"H Kantarijian","year":"2016","unstructured":"Kantarijian H, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740\u201353.","journal-title":"N Engl J Med"},{"key":"1129_CR15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.clml.2012.12.003","volume":"13","author":"P Kebriaei","year":"2013","unstructured":"Kebriaei P, Wilhelm K, Ravandi F, et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013;13:296\u2013301.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1129_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","volume":"55","author":"M Mohty","year":"2020","unstructured":"Mohty M, Malard F, Abecasis M, et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant. 2020;55:485\u201395.","journal-title":"Bone Marrow Transplant"},{"key":"1129_CR17","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/j.bbmt.2019.04.020","volume":"25","author":"DI Marks","year":"2019","unstructured":"Marks DI, Kebriaei P, Stelljes M, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019;25:1720\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1129_CR18","doi-asserted-by":"publisher","unstructured":"Kebriaei P, Cutler C, de Lima M, Giralt S, Lee SJ, Marks D, Merchant A, Stock W, van Besien K, Stelljes M. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transpl. 2018;53(4):449\u201356. https:\/\/doi.org\/10.1038\/s41409-017-0019-y.","DOI":"10.1038\/s41409-017-0019-y"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01129-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01129-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01129-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T07:47:20Z","timestamp":1748245640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01129-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1129"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01129-5","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"29 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This podcast was sponsored by Pfizer. No funding was provided for the authoring of this review. The authors received no honoria related to the development of this publication. Medical writing support was provided by Sarah Moore, MSc, of Engage Scientific Soloutions and funded by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marcos de Lima reports a consulting or advisory role at BMS, Autolus, and Pfizer; research funding from Miltenyi and Priothera; and he is on the data monitoring committee at AbbVie and Novartis. David I. Marks reports consulting at Pfizer and Nexcella.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}},{"value":"M.d.L. and D.M. made substantial contributions to the concept\/design of the manuscript, critically reviewed and revised the manuscript drafts, and provided final approval of the manuscript and enhanced content as submitted.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}